Organ-on-chip systems are advanced microfluidic platforms that replicate human organ function in a controlled laboratory environment. These systems use living human cells and dynamic flow conditions to simulate how organs such as the liver, lung, or heart respond to drugs, chemicals, and disease, providing more physiologically relevant data than traditional cell culture methods.

As drug development and preclinical research evolve, organ-on-chip technology is gaining traction as a powerful alternative to animal testing. The U.S. Food and Drug Administration (FDA) has announced plans to reduce and ultimately phase out certain animal testing requirements, encouraging the adoption of human-based models such as organ-on-chip systems to better predict human responses.

At the same time, the National Institutes of Health (NIH) is investing heavily in human-based research approaches, further accelerating the shift toward technologies that improve translational accuracy while reducing reliance on animal models.

By combining microfluidics, biomaterials, and tissue engineering, organ-on-chip systems enable researchers to model complex biological processes, study disease mechanisms, and evaluate drug safety with greater confidence, bridging the gap between in vitro testing and real human outcomes. Watch the video below to learn more.